BCAB

BioAtla (BCAB)

About BioAtla (BCAB)

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Details

Daily high

$2.10

Daily low

$1.96

Price at open

$2.06

52 Week High

$4.02

52 Week Low

$1.14

Market cap

96.7M

Dividend yield

0.00%

Volume

870

Avg. volume

1.8M

P/E ratio

-.92

BioAtla News